LON:DDDD 4D pharma (DDDD) Share Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About 4D pharma Stock (LON:DDDD) Get 4D pharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume1.21 million shsAverage Volume2.96 million shsMarket Capitalization£30.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview 4D pharma plc, together with its subsidiaries, develops live biotherapeutic products (LBPs) in the United Kingdom. The company develops therapeutic candidates, including MRx0518 for the treatment of cancer and immune-oncology diseases; MRx-4DP0004 for the treatment of asthma; MRx0029 and MRx0005 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, such as MRx1299 for solid tumors, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. In addition, the company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate MRx0518; strategic collaboration agreement with University of Texas MD Anderson for discovery and development of LBPs in oncology; and Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda, MRx0518 in patients with solid tumors, and to discover and develop LBPs for vaccines. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom. Read More Receive DDDD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 4D pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DDDD Stock News HeadlinesYieldMax® ETFs Announces Quarterly Distribution for the U.S. Stocks Target Double Distribution ETF (DDDD)September 30, 2026 | globenewswire.comYieldMax® ETFs Announces First Quarterly Distribution for the U.S. Stocks Target Double Distribution ETF (DDDD)July 1, 2026 | globenewswire.comWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock ahead of October 20. His system has spotted at least seven of the top 10 performers every year since 2016, including all ten in the 2022 bear market and every member of the Magnificent Seven before their run higher. Now Chaikin's Power Gauge is turning bullish on an under-the-radar company tied to next-generation AI data centers built under Executive Order 14363, technology he says uses 99 percent less electricity and space while offering far greater computing power.October 14 at 1:00 AM | Chaikin Analytics (Ad)You Already Own SCHD. This New ETF Pays Twice the Yield With One Simple SwapMarch 19, 2026 | 247wallst.com4D Molecular Therapeutics expands phase 3 trial enrollmentDecember 10, 2025 | msn.com4D Molecular Therapeutics Appoints New Chief Financial OfficerNovember 17, 2025 | msn.com4D Molecular Therapeutics Names Kristian Humer Chief Financial OfficerNovember 17, 2025 | marketwatch.comChardan Capital Maintains 4D Molecular Therapeutics (FDMT) Buy RecommendationNovember 12, 2025 | msn.comSee More Headlines DDDD Stock Analysis - Frequently Asked Questions How were 4D pharma's earnings last quarter? 4D pharma plc (LON:DDDD) announced its earnings results on Wednesday, September, 30th. The company reported ($14.06) earnings per share (EPS) for the quarter. What other stocks do shareholders of 4D pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that 4D pharma investors own include Amigo (AMGO), ImmuPharma (IMM), Omega Diagnostics Group (ODX), Alpine 4 (ALPP), Echostar (ECHO), Asiamet Resources (ARS) and Bidstack Group (BIDS). Company Calendar Last Earnings9/30/2020Today10/14/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolLON:DDDD CIKN/A Webwww.4dpharmaplc.com Phone+44-113-8950130FaxN/AEmployees106Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (15.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£31.94 million Net MarginsN/A Pretax MarginN/A Return on Equity-89.48% Return on Assets-42.64% Debt Debt-to-Equity Ratio39.50 Current Ratio5.21 Quick Ratio4.72 Sales & Book Value Annual Sales£718 thousand Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.44 Book ValueGBX 18 per share Price / BookN/AMiscellaneous Outstanding Shares180,340,000Free FloatN/AMarket Cap£30.05 million OptionableNot Optionable Beta2.63 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (LON:DDDD) was last updated on 11/8/2022 by MarketBeat.com Staff. From Our PartnersWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock...Chaikin Analytics | SponsoredTrump's about to unleash his Midterm WeaponTrump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower ...Monument Traders Alliance | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredHow one AI fund pays investors every ThursdayOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share 4D pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
